DelveInsight’s Schizophrenia - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market trends of the Schizophrenia for the seven major markets i.e. United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The Report covers the therapeutics market revenue; average cost of therapy, treatment practice and Schizophrenia forecasted market share for ten years to 2023 segmented by seven major markets. In addition, the report also includes global forecast of epidemiology of Schizophrenia till 2023.
Key Coverage and Benefits
• The report will help in developing business strategies by understanding the trends shaping and driving the global Schizophrenia market.
• Identifying patient populations in the global Schizophrenia market to improve product design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying the best opportunities for Schizophrenia therapeutics in each of the markets covered.
• To understand the future market competition in the global Schizophrenia therapeutics market and Insightful review of the key market drivers and barriers.
Scope
• Report covers the disease overview including etiology, path physiology, symptoms, diagnosis, disease management, and current treatment options.
• Marketed information including available prescription drugs, its patent and exclusivity details followed by drug sales till 2023.
• The Report also covers the detailed global historical and forecasted epidemiological data covering United States, EU5, Japan and rest of the word from 2013-2023.
• It also provides Schizophrenia for United States, EU5 and Japan from 2013 and forecasted Market to 2023.
Note: This report requires 7-10 business days to complete.
'
Table of Contents
• Schizophrenia overview
• Pathophysiology
• Symptoms of disease
• Etiology of disease
• Diagnosis of disease
• Treatment of disease
• Overview of Marketed drugs
• Drug Description
• Mechanism of Action
• Pharmacokinetics Properties
• Marketed Details
• Patent Information
• Patent Exclusivity Expiry Assessment United States (US)
• Patents Details
• Historical and Forecasted sales of marketed molecules in the Global Schizophrenia Market
• Global Epidemiology of Schizophrenia Forecasted to 2023
• Global Market (2013-2015)
• Global Forecasted Market (2016-2023)
• Global Market by Geography
• Market of US (2013-2015)
• Forecasted Market of US (2016-2023)
• Market of Europe
• Market of Germany (2013-2015)
• Forecasted Market of Germany (2016-2023)
• Market of United Kingdom (2013-2015)
• Forecasted Market of United Kingdom (2016-2023)
• Market of France (2013-2015)
• Forecasted Market of France (2016-2023)
• Market of Italy (2013-2015)
• Forecasted Market of Italy (2016-2023)
• Market of Spain (2013-2015)
• Forecasted Market of Spain (2016-2023)
• Market of Japan (2013-2015)
• Forecasted Market of Japan (2016-2023)
• Market of ROW (2013-2015)
• Forecasted Market of ROW (2016-2023)
• Appendix
• Report Methodology
• Consulting Services
• Disclaimer
• Report Purchase Options
• About DelveInsight
List of Tables
• Table 1: Drug Description
• Table 2: Drug, Marketed Details United States (US)
• Table 3: Drug, Patent Number Specific Patent Expiry in US (Year), 2015
• Table 4: Drug, Patent Details for US
• Table 5: Schizophrenia Drug Sales (USD Millions)
• Table 6: Global Epidemiology of Schizophrenia (2013-2023)
• Table 7: Schizophrenia Global Market (USD Millions), (2013-2015)
• Table 8: Schizophrenia Global Market (USD Millions), (2016-2023)
• Table 9: Schizophrenia US Market (USD Millions), (2013-2015)
• Table 10: Schizophrenia US Market (USD Millions), (2016-2023)
• Table 11: Schizophrenia Germany Market (USD Millions), (2013-2015)
• Table 12: Schizophrenia Germany Market (USD Millions), (2016-2023)
• Table 13: Schizophrenia United Kingdom Market (USD Millions), (2013-2015)
• Table 14: Schizophrenia United Kingdom Market (USD Millions), (2016-2023)
• Table 15: Schizophrenia France Market (USD Millions), (2013-2015)
• Table 16: Schizophrenia France Market (USD Millions), (2016-2023)
• Table 17: Schizophrenia Italy Market (USD Millions), (2013-2015)
• Table 18: Schizophrenia Italy Market (USD Millions), (2016-2023)
• Table 19: Schizophrenia Spain Market (USD Millions), (2013-2015)
• Table 20: Schizophrenia Spain Market (USD Millions), (2016-2023)
• Table 21: Schizophrenia Japan Market (USD Millions), (2013-2015)
• Table 22: Schizophrenia Japan Market (USD Millions), (2016-2023)
• Table 23: Schizophrenia ROW Market (USD Millions), (2013-2015)
• Table 24: Schizophrenia ROW Market (USD Millions), (2016-2023)
List of Figures
• Figure 1: Schizophrenia Drug Sales (USD Millions)
• Figure 2: Global Epidemiology of Schizophrenia (2013-2023)
• Figure 3: Schizophrenia Global Market (USD Millions), (2013-2015)
• Figure 4: Schizophrenia Global Market (USD Millions), (2016-2023)
• Figure 5: Schizophrenia US Market (USD Millions), (2013-2015)
• Figure 6: Schizophrenia US Market (USD Millions), (2016-2023)
• Figure 7: Schizophrenia Germany Market (USD Millions), (2013-2015)
• Figure 8: Schizophrenia Germany Market (USD Millions), (2016-2023)
• Figure 9: Schizophrenia United Kingdom Market (USD Millions), (2013-2015)
• Figure 10: Schizophrenia United Kingdom Market (USD Millions), (2016-2023)
• Figure 11: Schizophrenia France Market (USD Millions), (2013-2015)
• Figure 12: Schizophrenia France Market (USD Millions), (2016-2023)
• Figure 13: Schizophrenia Italy Market (USD Millions), (2013-2015)
• Figure 14: Schizophrenia Italy Market (USD Millions), (2016-2023)
• Figure 15: Schizophrenia Spain Market (USD Millions), (2013-2015)
• Figure 16: Schizophrenia Spain Market (USD Millions), (2016-2023)
• Figure 17: Schizophrenia Japan Market (USD Millions), (2013-2015)
• Figure 18: Schizophrenia Japan Market (USD Millions), (2015-2023)
• Figure 19: Schizophrenia ROW Market (USD Millions), (2013-2015)
• Figure 20: Schizophrenia ROW Market (USD Millions), (2016-2023)
• Janssen Pharmaceuticals
• Eli Lilly and Company
• Roche
• Alkermes
• EnVivo Pharmaceuticals
• Bristol-Myers Squibb
• Boehringer Ingelheim
• Avineuro Pharmaceuticals
• Addex Pharmaceuticals
